|Dr. Lawrence M. Blatt MBA, Ph.D.||CEO & Chairman||872.58k||N/A||1962|
|Dr. Leonid Beigelman Ph.D.||Pres & Director||702.25k||N/A||1959|
|Dr. Julian A. Symons DPHIL||Exec. VP & Chief Scientific Officer||618.82k||N/A||1961|
|Ms. Lesley Ann Calhoun CPA||Exec. VP & CFO||N/A||N/A||1966|
|Ms. Lucinda Y. Quan J.D.||Exec. VP, Chief Bus. Officer & Gen. Counsel||N/A||N/A||1972|
|Mr. John Fry||Exec. VP of Clinical Devel.||N/A||N/A||1963|
|Dr. Matthew W. McClure M.D.||Exec. VP & Chief Medical Officer||N/A||N/A||1972|
|Dr. Sushmita M. Chanda DABT, Ph.D.||Exec. VP of Translational Safety Sciences||N/A||N/A||1966|
|Dr. David B. Smith Ph.D.||Exec. VP & Head of Chemical Operations||N/A||N/A||N/A|
|Dr. Tse-I Lin Ph.D.||VP of Early Compound Devel. & Belgian Site Head||N/A||N/A||N/A|
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.